Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for PALI.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2006. Start Trial.
Date Value
June 30, 2026 121.75M
March 31, 2026 127.36M
December 31, 2025 129.38M
September 30, 2025 3.212M
June 30, 2025 2.62M
March 31, 2025 5.331M
December 31, 2024 7.492M
September 30, 2024 6.608M
June 30, 2024 9.949M
March 31, 2024 10.06M
December 31, 2023 11.31M
September 30, 2023 14.08M
June 30, 2023 15.80M
March 31, 2023 13.75M
December 31, 2022 12.48M
September 30, 2022 12.43M
June 30, 2022 4.211M
March 31, 2022 4.792M
December 31, 2021 7.365M
September 30, 2021 3.92M
June 30, 2021 -9.444M
March 31, 2021 7.729M
December 31, 2020 -7.099M
September 30, 2020 14.12M
June 30, 2020 16.23M
Date Value
March 31, 2020 9.978M
December 31, 2019 5.126M
September 30, 2019 7.043M
June 30, 2019 1.963M
March 31, 2019 3.272M
December 31, 2018 6.050M
September 30, 2018 4.479M
June 30, 2018 6.175M
March 31, 2018 6.607M
December 31, 2017 8.515M
September 30, 2017 11.56M
June 30, 2017 7.693M
March 31, 2017 9.780M
December 31, 2016 11.33M
September 30, 2016 -3.785M
June 30, 2016 0.8365M
March 31, 2016 -0.1694M
December 31, 2015 4.967M
September 30, 2015 8.903M
June 30, 2015 14.54M
March 31, 2015 19.36M
December 31, 2014 17.72M
September 30, 2014 20.90M
June 30, 2014 24.03M
March 31, 2014 26.90M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics